Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Aug;64(2):519-530.
doi: 10.1007/s10840-021-01116-6. Epub 2022 Jan 18.

Junctional AV ablation in patients with atrial fibrillation undergoing cardiac resynchronization therapy (JAVA-CRT): results of a multicenter randomized clinical trial pilot program

Jonathan S Steinberg  1   2 , John Gorcsan  3 , Alexander Mazur  4 , Sandeep K Jain  5 , Mayer Rashtian  6 , G Stephen Greer  7 , Ignatius Zarraga  8 , Margot Vloka  9 , Michele Murphy Cook  10 , Tariq Salam  11 , Stavros Mountantonakis  12 , Hiroko Beck  13 , Jonathan Silver  14 , Mehmet Aktas  15 , Charles Henrikson  16 , Robert D Schaller  17 , Andrew E Epstein  17 , Scott McNitt  18 , Susan Schleede  18 , Derick Peterson  19 , Ilan Goldenberg  18 , Wojciech Zareba  18
Affiliations
Randomized Controlled Trial

Junctional AV ablation in patients with atrial fibrillation undergoing cardiac resynchronization therapy (JAVA-CRT): results of a multicenter randomized clinical trial pilot program

Jonathan S Steinberg et al. J Interv Card Electrophysiol. 2022 Aug.

Abstract

Introduction: Cardiac resynchronization therapy (CRT) improves outcomes in sinus rhythm, but the data in atrial fibrillation (AF) is limited. Atrio-ventricular junctional ablation (AVJA) has been proposed as a remedy. The objective was to test if AVJA results in LV end-systolic volume (ESV) reduction ≥ 15% from baseline to 6 months.

Methods: The trial was a prospective multicenter randomized trial in 26 patients with permanent AF who were randomized 1:1 to CRT-D with or without AVJA.

Results: LVESV improved similarly by at least 15% in 5/10 (50%) in the CRT-D-only arm and in 6/12 (50%) in the AVJA + CRT-D arm (OR = 1.00 [0.14, 7.21], p = 1.00). In the CRT-D-only arm, the median 6-month improvement in LVEF was 9.2%, not different from the AVJA + CRT-D arm, 8.2%. When both groups were combined, a significant increase in LVEF was observed (25.4% at baseline vs 36.2% at 6 months, p = 0.002). NYHA class from baseline to 6 months for all patients combined improved 1 class in 15 of 24 (62.5%), whereas 9 remained in the same class and 0 degraded to a worse class.

Conclusion: In patients with permanent AF, reduced LVEF, and broad QRS who were eligible for CRT, there was insufficient evidence that AVJA improved echocardiographic or clinical outcomes; the results should be interpreted in light of a smaller than planned sample size. CRT, however, seemed to be effective in the combined study cohort overall, suggesting that CRT can be reasonably deployed in patients with AF.

Trial registration: ClinicalTrials.gov Identifier: NCT02946853.

Keywords: AV junctional ablation; Atrial fibrillation; Biventricular pacing; Cardiac resynchronization therapy; Cardiomyopathy; Heart failure.

PubMed Disclaimer

Conflict of interest statement

JSS (research support from NHLBI, AliveCor, Atricure, Allergan; consulting with Medtronic, Corfigo, Hillrom, Braveheart, National Cardiac, Cardioelectra; equity with AliveCor, Braveheart, National Cardiac); JG (research support from EBR Systems, V-Wave Ltd, AADi Pharmaceuticals); SKJ (research support from Medtronic, Boston Scientific and Abbott); WZ (research support from Boston Scientific, Biotronik, LivaNova; consulting with Medtronic, Abbott). The remaining authors have indicated that they have no relevant conflicts to report.

Figures

Fig. 1
Fig. 1
Individual changes in left ventricular ejection fraction (LVEF) between baseline and 6 months (black are CRT-D only and red are CRT-D with AVJA)
Fig. 2
Fig. 2
Left ventricular ejection fraction (LVEF) at baseline and at 6 months, in all patients combined (with and without AVJA)
Fig. 3
Fig. 3
Changes in New York Heart Association (NYHA) class over 6 months, by randomization arm (CRT-D only vs CRT-D and AVJA)
Fig. 4
Fig. 4
Changes in NYHA class over 6 months in both arms combined
See this image and copyright information in PMC

References

    1. Voors AA, Anker SD, Bueno H, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Eur Heart J. 2016;37:2129–2200. doi: 10.1093/eurheartj/ehw128. - DOI - PubMed
    1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guidelines for the management of heart failure. J Am Coll Cardiol. 2013;62:e147–239. doi: 10.1016/j.jacc.2013.05.019. - DOI - PubMed
    1. Echouffo-Tcheugui JB, Masoudi FA, Bao H, Curtis JP, Heidenreich PA, Fonarow GC. Body mass index and outcomes of cardiac resynchronization with implantable cardioverter-defibrillator therapy in older patients with heart failure. Eur J Heart Fail. 2019;21:1093–1102. doi: 10.1002/ejhf.1552. - DOI - PubMed
    1. Healy JS, Hohnloser SH, Exner DV, et al. Cardiac resynchronization therapy in patients with permanent atrial fibrillation; results from the Resynchronization for Ambulatory Heart Failure Trial (F-RAFT) Circ Heart Fail. 2012;5:566–570. doi: 10.1161/CIRCHEARTFAILURE.112.968867. - DOI - PubMed
    1. Hayes DL, Boehmer JP, Day JD, et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm. 2011;8:1460–1475. doi: 10.1016/j.hrthm.2011.04.015. - DOI - PubMed

Publication types

Associated data